Ipamorelin Results: What the Clinical Data Actually Shows
Clinical outcomes, dose-response data, and what to realistically expect from Ipamorelin treatment.
Retatrutide vs Tirzepatide vs Semaglutide: Trial Outcomes
| Metric | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Drug class | GIP/GLP-1/Glucagon triple | GIP/GLP-1 dual | GLP-1 single |
| Max dose (studied) | 24mg weekly | 15mg weekly | 2.4mg weekly |
| Peak weight loss (mean) | 24.2% | 22.5% | 15.0% |
| Trial duration | 48 weeks (Ph2) | 72 weeks (Ph3) | 68 weeks (Ph3) |
| Trial size | 338 participants | 2,539 participants | 1,961 participants |
| FDA approval (obesity) | Not approved | Approved (Zepbound, 2023) | Approved (Wegovy, 2021) |
| Thermogenesis effect | Yes — glucagon-driven | Minimal | Minimal |
Sources: TRIUMPH-1 (NEJM 2023), SURMOUNT-1 (NEJM 2022), STEP-1 (NEJM 2021).
What Happens When You Stop Taking Ipamorelin?
Weight regain after stopping Ipamorelin is expected. TRIUMPH-1 included a 24-week follow-up period after the active treatment phase. Participants regained a portion of lost weight as the drug's appetite-suppressing and thermogenic effects diminished.
Frequently Asked Questions
How much weight can you lose on Ipamorelin?
Weight loss results with Ipamorelin depend on dose, duration, and individual metabolic response. Clinical trial data provides the best available evidence — consult the published research and speak with a healthcare provider for personalized expectations.
How long does Ipamorelin take to work?
Most peptides in this class show initial weight loss effects within the first 4–8 weeks. Maximum results typically emerge between weeks 24–48 of continuous treatment.
References & Sources
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.